Cited by 224Treatment of Major DepressionElectroconvulsive Therapy StudiesTryptophan and brain disorders

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine

Open access

Lally, Níall, Nugent, Allison C, Luckenbaugh, David A, Niciu, Mark J, Roiser, Jonathan P, Zarate, Carlos A·2015·Journal of Psychopharmacology

DOI 10.1177/0269881114568041PMC PMC5116382

Open this paper in CoChat — free account

Abstract

Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists. In this exploratory re-analysis, we assessed whether administration of rapid-acting antidepressant ketamine was associated specifically with reduced anhedonia in medication-free treatment-refractory patients with major depressive disorder in an open-label investigation. Additionally, participants received either oral riluzole or placebo daily beginning 4 hours post-infusion. A subgroup of patients underwent fluorodeoxyglucose positron emission tomography scans at baseline (1–3 days pre-infusion) and 2 hours post-ketamine infusion. Anhedonia rapidly decreased following a single ketamine infusion; this was sustained for up to three days, but was not altered by riluzole. Reduced anhedonia correlated with increased glucose metabolism in the hippocampus and dorsal anterior cingulate cortex (dACC) and decreased metabolism in the inferior frontal gyrus and orbitofrontal cortex (OFC). The tentative relationship between change in anhedonia and glucose metabolism remained significant in dACC and OFC, and at trend level in the hippocampus, a result not anticipated, when controlling for change in total depression score. Results, however, remain tenuous due to the lack of a placebo control for ketamine. In addition to alleviating overall depressive symptoms, ketamine could possess anti-anhedonic potential in major depressive disorder, which speculatively, may be mediated by alterations in metabolic activity in the hippocampus, dACC and OFC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/0269881114568041

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm
Zhang, Y., Brady, M., & Smith, S. M. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.906424 · Cited by 7,628
Research domain criteria (RDoC): toward a new classification framework for research on mental disorders
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091379 · Cited by 7,067
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citation
Learning the value of information in an uncertain world
Behrens, T. E. J., Woolrich, M. W., Walton, M. E., & Rushworth, M. F. S. (2007) · Nature Neuroscience · doi:10.1038/nn1954 · Cited by 2,053
Abstract reward and punishment representations in the human orbitofrontal cortex
O'Doherty, J., Kringelbach, M. L., Rolls, E. T., Hornak, J., & Andrews, C. (2001) · Nature Neuroscience · doi:10.1038/82959 · Cited by 2,003
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778

Show all 70 references

Research works printed but not linked: 4

Brooks RA, 1982, J Nucl Med, 23, 538
First MB, 2002, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition
Papp M, 1993, Pol J Pharmacol, 45, 549
Sackeim HA, 2001, J Clin Psychiatry, 62, 10

Sorted by citations

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citation
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Prefrontal cortex and depression
Pizzagalli, D. A., & Roberts, A. C. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01101-7 · Cited by 667
Reward Processing in Depression: A Conceptual and Meta-Analytic Review Across fMRI and EEG Studies
Keren, H., O’Callaghan, G., Vidal-Ribas, P., Buzzell, G. A., Brotman, M. A., Leibenluft, E., Pan, P. M., Meffert, L., Kaiser, A., Wolke, S., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101124 · Cited by 521
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
Self-citation
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
The orbitofrontal cortex and emotion in health and disease, including depression
Rolls, E. T. (2017) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.09.021 · Cited by 343
Disrupted habenula function in major depression
Lawson, R. P., Nord, C. L., Seymour, B., Thomas, D. L., Dayan, P., Pilling, S., & Roiser, J. P. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.81 · Cited by 210
Self-citation
Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?
Pizzagalli, D. A. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220423 · Cited by 214
A non-reward attractor theory of depression
Rolls, E. T. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.05.007 · Cited by 180
Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review
Cao, B., Zhu, J., Zuckerman, H., Rosenblat, J. D., Brietzke, E., Pan, Z., Subramanieapillai, M., Park, C., Lee, Y., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.002 · Cited by 175
Anhedonia as a central factor in depression: Neural mechanisms revealed from preclinical to clinical evidence
Wang, S., Leri, F., & Rizvi, S. J. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110289 · Cited by 171
Anhedonia in depression and schizophrenia: A transdiagnostic challenge
Lambert, C. M., Silva, S. D., Ceniti, A. K., Rizvi, S. J., Foussias, G., & Kennedy, S. H. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12854 · Cited by 170
The effects of low‐dose ketamine on the prefrontal cortex and amygdala in treatment‐resistant depression: A randomized controlled study
Li, C., Chen, M., Lin, W., Hong, C., Yang, B., Liu, R., Tu, P., & Su, T. (2016) · Human Brain Mapping · doi:10.1002/hbm.23085 · Cited by 152
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials
Ballard, E. D., Wills, K. E., Lally, N., Richards, E. M., Luckenbaugh, D. A., Walls, T. L., Ameli, R., Niciu, M. J., Brutsché, N. E., Park, L., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.057 · Cited by 155
Self-citation
The efficacy of vortioxetine on anhedonia in patients with major depressive disorder
Cao, B., Park, C., Subramaniapillai, M., Lee, Y., Iacobucci, M., Mansur, R. B., Zuckerman, H., Phan, L., & McIntyre, R. S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00017 · Cited by 139
Overview of Glutamatergic Dysregulation in Central Pathologies
Miladinovic, T., Nashed, M. G., & Singh, G. (2015) · Biomolecules · doi:10.3390/biom5043112 · Cited by 135
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
“Ketamine also rapidly improves anhedonia in depressed patients (29, 30).”
BackgroundSelf-citation
Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex
Alexander, L., Gaskin, P. L. R., Sawiak, S. J., Fryer, T. D., Hong, Y. T., Cockcroft, G. J., Clarke, H. F., & Roberts, A. C. (2019) · Neuron · doi:10.1016/j.neuron.2018.11.021 · Cited by 120
Ketamine for treatment-resistant depression: recent developments and clinical applications
Kirshenbaum, J. S., Murrough, J. W., & Iosifescu, D. V. (2016) · Evidence-Based Mental Health · doi:10.1136/eb-2016-102355 · Cited by 122
Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals
Mkrtchian, A., Evans, J. W., Kraus, C., Yuan, P., Kadriu, B., Nugent, A. C., Roiser, J. P., & Zarate, C. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00878-1 · Cited by 110
Self-citation
The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits
Witkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233627 · Cited by 105
Roles of the medial and lateral orbitofrontal cortex in major depression and its treatment
Zhang, B., Rolls, E. T., Wang, X., Xie, C., Cheng, W., & Feng, J. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02380-w · Cited by 107
Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature
Ionescu, D. F., Felicione, J. M., Gosai, A., Cusin, C., Shin, P., Shapero, B. G., & Deckersbach, T. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000179 · Cited by 91
Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes
Clarke, M., Razmjou, S., Prowse, N. A., Dwyer, Z., Litteljohn, D., Pentz, R., Anisman, H., & Hayley, S. P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.021 · Cited by 94
Changes in positive and negative affect during pharmacological treatment and cognitive therapy for major depressive disorder: A secondary analysis of two randomized controlled trials
Dunn, B. D., German, R. E., Khazanov, G., Xu, C., Hollon, S. D., & DeRubeis, R. J. (2020) · Clinical Psychological Science · doi:10.1177/2167702619863427 · Cited by 92
Glutamatergic Modulators in Depression
Henter, I. D., SOUSA, R. T. D., & Zarate, C. A. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000183 · Cited by 99
Self-citation
The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research
Amidfar, M., Woelfer, M., Réus, G. Z., Quevedo, J., Walter, M., & Kim, Y. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109668 · Cited by 95
Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
McIntyre, R. S., Loft, H., & Christensen, M. C. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s296451 · Cited by 87
The anterior cingulate cortex as a key locus of ketamine’s antidepressant action
Alexander, L., Jelen, L. A., Mehta, M. A., & Young, A. H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.003 · Cited by 83
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
Self-citation
Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study
Chen, M.-H., Lin, W.-C., Tu, P.-C., Li, C.-T., Bai, Y.-M., Tsai, S.-J., & Su, T.-P. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.022 · Cited by 78
Rapid-acting antidepressants
Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 80
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
Lee, Y., Syeda, K., Maruschak, N. A., Cha, D. S., Mansur, R. B., Wium-Andersen, I. K., Woldeyohannes, H. O., Rosenblat, J. D., & McIntyre, R. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000441 · Cited by 74
Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales
Ballard, E. D., Yarrington, J. S., Farmer, C., Lener, M. S., Kadriu, B., Lally, N., Williams, D., Machado‐Vieira, R., Niciu, M. J., Park, L., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.01.027 · Cited by 78
Self-citation
(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism
Riggs, L. M., Aracava, Y., Zanos, P., Fischell, J., Albuquerque, E. X., Pereira, E. F. R., Thompson, S. M., & Gould, T. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0443-3 · Cited by 66
Association between anhedonia and suicidal events in patients with mood disorders: A 3‐year prospective study
Ducasse, D., Dubois, J., Jaussent, I., Azorin, J., Étain, B., Gard, S., Henry, C., Bougerol, T., Kahn, J., Aubin, V., et al. (2020) · Depression and Anxiety · doi:10.1002/da.23072 · Cited by 70
The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression
Smith, A. L. W., Harmer, C. J., Cowen, P. J., & Murphy, S. E. (2023) · CNS Drugs · doi:10.1007/s40263-023-01014-7 · Cited by 70
A Focus on the Functions of Area 25
Alexander, L., Clarke, H. F., & Roberts, A. (2019) · Brain Science · doi:10.3390/brainsci9060129 · Cited by 54
NMDA antagonist treatment of depression
Williams, N., & Schatzberg, A. F. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.001 · Cited by 68
Metabolic syndrome, depression and anhedonia among young adults
Moreira, F. P., Jansen, K., Cardoso, T. D. A., Mondin, T. C., Vieira, I. S., Magalhães, P. V. D. S., Kapczinski, F. P., Souza, L. D. D. M., da Silva, R. A., Oses, J. P., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.009 · Cited by 62
Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study
Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Su, T.-P. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.008 · Cited by 63
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
Pettorruso, M., Guidotti, R., d’Andrea, G., Risio, L. D., D’Andrea, A., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115378 · Cited by 60
Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia?
Szczypiński, J., & Gola, M. K. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0091 · Cited by 62
Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities
Shinohara, R., Aghajanian, G. K., & Abdallah, C. G. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.006 · Cited by 54
The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits
Nogo, D., Jasrai, A. K., Kim, H., Nasri, F., Ceban, F., Lui, L. M. W., Rosenblat, J. D., Vinberg, M., Ho, R., & McIntyre, R. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06105-9 · Cited by 54
Hedonic sensitivity to low-dose ketamine is modulated by gonadal hormones in a sex-dependent manner
Saland, S. K., Schoepfer, K. J., & Kabbaj, M. (2016) · Scientific Reports · doi:10.1038/srep21322 · Cited by 54
Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression
Delfino, R. S., Del-Porto, J. A., Surjan, J. C., Magalhães, E. T. P., Sant, L. C. D., Lucchese, A. C., Tuena, M. A., Nakahira, C., Fava, V. A. R., Steglich, M. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.056 · Cited by 54
Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder
Sterpenich, V., Vidal, S., Hofmeister, J., Michalopoulos, G., Bancila, V., Warrot, D., Dayer, A., Desseilles, M., Aubry, J.-M., Kosel, M., et al. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002667 · Cited by 53
The neurophysiology of ketamine: an integrative review
McMillan, R. L., & Muthukumaraswamy, S. D. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0090 · Cited by 51
Convergence of distinct signaling pathways on synaptic scaling to trigger rapid antidepressant action
Suzuki, K., Kim, J.-W., Nosyreva, E., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109918 · Cited by 49
Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression
Vasavada, M. M., Loureiro, J. R., Kubicki, A., Sahib, A. K., Wade, B., Hellemann, G., Espinoza, R. T., Congdon, E. L., Narr, K. L., & Leaver, A. M. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.06.015 · Cited by 51
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence
Rodrigues, N. B., McIntyre, R. S., Lipsitz, O., Cha, D. S., Lee, Y. L., Gill, H., Majeed, A., Phan, L., Nasri, F., Ho, R., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.083 · Cited by 53
Anhedonia and Suicide
Auerbach, R. P., Pagliaccio, D., & Kirshenbaum, J. S. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_358 · Cited by 51
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study
Gargoloff, P. D., Corral, R. M., Herbst, L., Márquez, M., Martinotti, G., & Gargoloff, P. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2557 · Cited by 47
The ventromedial prefrontal cortex and emotion regulation: lost in translation?
Alexander, L., Wood, C. M., & Roberts, A. (2022) · The Journal of Physiology · doi:10.1113/jp282627 · Cited by 48
A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders
Guessoum, S. B., Strat, Y. L., Dubertret, C., & Mallet, J. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109862 · Cited by 50
Altered neural activity in the reward-related circuit and executive control network associated with amelioration of anhedonia in major depressive disorder by electroconvulsive therapy
Zhang, T., He, K., Bai, T., Lv, H., Xie, X., Nie, J., Xie, W., Zhu, C., Wang, K., & Tian, Y. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110193 · Cited by 44
Reliability of 7T1H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation
Lally, N., An, L., Banerjee, D., Niciu, M. J., Luckenbaugh, D. A., Richards, E. M., Roiser, J. P., Shen, J., Zarate, C. A., & Nugent, A. C. (2015) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24970 · Cited by 44
Self-citation
Rapid-Acting Antidepressants
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. X.-Y. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 45
Apathy and Motivation: Biological Basis and Drug Treatment
Costello, H., Husain, M., & Roiser, J. P. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022423-014645 · Cited by 51
Self-citation
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.
Witkin, J. M., Mitchell, S. N., Wafford, K. A., Carter, G., Gilmour, G., Li, J., Eastwood, B. J., Overshiner, C. D., Li, X., Rorick‐Kehn, L. M., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.238121 · Cited by 42
Enhanced fear memories and brain glucose metabolism (18F-FDG-PET) following sub-anesthetic intravenous ketamine infusion in Sprague-Dawley rats
Radford, K. D., Park, T. Y., Jaiswal, S., Pan, H., Knutsen, A. K., Zhang, M., Driscoll, M. Y., Osborne-Smith, L., Dardzinski, B. J., & Choi, K. H. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0310-8 · Cited by 43
Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder
Sahib, A. K., Loureiro, J. R., Vasavada, M. M., Kubicki, A., Joshi, S. H., Wang, K., Woods, R. P., Congdon, E. L., Wang, D. J. J., Boucher, M., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.017 · Cited by 43
Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables
Perna, G., Alciati, A., Daccò, S., Grassi, M., & Caldirola, D. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0289 · Cited by 47
Stress to inflammation and anhedonia: Mechanistic insights from preclinical and clinical models
Boyle, C. C., Bower, J. E., Eisenberger, N. I., & Irwin, M. R. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105307 · Cited by 46
Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder
Nugent, A. C., Robinson, S. E., Coppola, R., & Zarate, C. A. (2016) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2016.06.006 · Cited by 42
Self-citation
APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline
Fang, W., Xiao, N., Zeng, G., Bi, D., Dai, X., Mi, X., Ye, Q., Chen, X., & Zhang, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01631-0 · Cited by 42
Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis
Conley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
Characterizing the subtype of anhedonia in major depressive disorder: A symptom-specific multimodal MRI study
Liu, X., Li, L., Li, M., Ren, Z., & Ma, P. (2020) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2020.111239 · Cited by 39
Vitamin D Deficiency and Depressive Symptomatology in Psychiatric Patients Hospitalized with a Current Depressive Episode: A Factor Analytic Study
von Känel, R., Fardad, N., Steurer, N., Horak, N., Hindermann, E., Fischer, F., & Gessler, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138550 · Cited by 38
Antianhedonic effect of repeated ketamine infusions in patients with treatment resistant depression
Wilkowska, A., Wiglusz, M. S., Gałuszko-Wegielnik, M., Włodarczyk, A., & Cubała, W. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.704330 · Cited by 35
“5 mg/kg ketamine after a 2-week washout period, which also confirmed a rapid antianhedonic effect of ketamine (17).”
Background
Neural mapping of anhedonia across psychiatric diagnoses: A transdiagnostic neuroimaging analysis
Schaub, A.-C., Kirschner, M., Schweinfurth, N., Mählmann, L., Kettelhack, C., Engeli, E., Doll, J. P. K., Borgwardt, S., Lang, U. E., Kaiser, S., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102825 · Cited by 38
A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings
Pulcu, E., Guinea, C., Cowen, P. J., Murphy, S. E., & Harmer, C. J. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01183-1 · Cited by 35
Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study
Pollak, T. A., Simoni, S. D., Barimani, B., Zelaya, F. O., Stone, J. M., & Mehta, M. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4078-8 · Cited by 35
Probabilistic Reinforcement Learning and Anhedonia
Kangas, B. D., Der‐Avakian, A., & Pizzagalli, D. A. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_349 · Cited by 36
Systemic Inflammation and Anhedonic Responses to an Inflammatory Challenge in Adults With Major Depressive Disorder: A Randomized Controlled Trial
Savitz, J. B., Figueroa‐Hall, L. K., Teague, T. K., Yeh, H., Zheng, H., Kuplicki, R., Burrows, K., El-Sabbagh, N. S., Thomas, M., Ewers, I., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240142 · Cited by 34
Ketamine Suppresses the Ventral Striatal Response to Reward Anticipation: A Cross-Species Translational Neuroimaging Study
François, J., Grimm, O., Schwarz, A. J., Schweiger, J. I., Haller, L., Risterucci, C., Böhringer, A., Zang, Z., Tost, H., Gilmour, G., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.291 · Cited by 34
Altered hippocampal subfield volumes in major depressive disorder with and without anhedonia
Wu, C., Jia, L., Mu, Q., Fang, Z., Hamoudi, H. J. A. S., Huang, M., Hu, S., Zhang, P., Xu, Y., & Lu, S. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05001-6 · Cited by 29
Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders
Zarate, C. A., & Machado‐Vieira, R. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.249 · Cited by 33
Self-citation
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Jawad, M. Y., Vincenzo, J. D. D., Badulescu, S., Teopiz, K. M., Tabassum, A., Ceban, F., Mckenzie, A., Meshkat, S., Rosenblat, J. D., Ho, R., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109299 · Cited by 32
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“(142) 20, 0 (18)F-FDG-PET Whole-brain CMRGlu and ROIs in ventral striatum and OFC N/A Pre-treatment and 2 h post-treatment”
Background
Preliminary evidence that ketamine alters anterior cingulate resting-state functional connectivity in depressed individuals
Alexander, L., Hawkins, P. C. T., Evans, J. W., Mehta, M. A., & Zarate, C. A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02674-1 · Cited by 29
Self-citation
Eficacia y seguridad de la ketamina en depresión bipolar: una revisión sistemática
Alberich, S., Martínez‐Cengotitabengoa, M., López‐Mahía, P., Zorrilla, E. P., Núñez, N., Vieta, E., & González-Pinto, A. M. (2016) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2016.05.005 · Cited by 30
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657714 · Cited by 33
Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression
Zheng, W., Gu, L.-M., Sun, C.-H., Zhou, Y., Wang, C., Lan, X., Zhang, B., & Ning, Y. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.105 · Cited by 31
Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine
Zavaliangos‐Petropulu, A., Al‐Sharif, N., Taraku, B., Leaver, A. M., Sahib, A. K., Espinoza, R. T., & Narr, K. L. (2022) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2022.11.005 · Cited by 31
Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review
Kwaśny, A., Kwaśna, J., Wilkowska, A., Szarmach, J., Słupski, J., Włodarczyk, A., & Cubała, W. J. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.014 · Cited by 27
SIRT2 inhibition reverses anhedonia in the VGLUT1+/− depression model
Muñoz-Cobo, I., Belloch, F. B., Diaz-Perdigón, T., Puerta, E., & Tordera, R. M. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.07.045 · Cited by 28
Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression
Hochschild, A., Keilp, J. G., Madden, S. P., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.055 · Cited by 25
Non-reward neural mechanisms in the orbitofrontal cortex
Rolls, E. T., & Deco, G. (2016) · Cortex · doi:10.1016/j.cortex.2016.06.023 · Cited by 27
Translational Assessments of Reward Responsiveness in the Marmoset
Wooldridge, L. M., Bergman, J., Pizzagalli, D. A., & Kangas, B. D. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa090 · Cited by 27
Chronic oral ketamine prevents anhedonia and alters neuronal activation in the lateral habenula and nucleus accumbens in rats under chronic unpredictable mild stress
Kingir, E., Sevinc, C., & Ünal, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109468 · Cited by 28
Chemogenetics identifies separate area 25 brain circuits involved in anhedonia and anxiety in marmosets
Wood, C. M., Alexander, L., Alsiö, J., Santangelo, A. M., McIver, L. B., Cockcroft, G. J., & Roberts, A. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade1779 · Cited by 26
Copper and anti-anhedonic effect of ketamine in treatment-resistant depression
Słupski, J., Cubała, W. J., Górska, N., Słupska, A., & Gałuszko‐Węgielnik, M. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110268 · Cited by 25
Neural signatures of saliency-mapping in anhedonia: A narrative review
Pisoni, A., Davis, S. W., & Smoski, M. J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114123 · Cited by 25
Efficacy and safety of ketamine in bipolar depression: A systematic review
Alberich, S., Martínez‐Cengotitabengoa, M., López‐Mahía, P., Zorrilla, I., Núñez, N., Vieta, E., & González-Pinto, A. M. (2017) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2017.05.004 · Cited by 24
Resting-state connectivity studies as a marker of the acute and delayed effects of subanaesthetic ketamine administration in healthy and depressed individuals: A systematic review
Kotoula, V., Webster, T., Stone, J. M., & Mehta, M. A. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211055426 · Cited by 22
Pharmacological Treatments for Anhedonia
Klein, M. E., Grice, A. B., Sheth, S., Go, M., & Murrough, J. W. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_357 · Cited by 26

Authors: Lally, N., Nugent, A. C., Luckenbaugh, D. A., Niciu, M. J., Roiser, J. P., & Zarate, C. A.
Affiliations: National Institutes of Health (US)
University College London (GB)
Corresponding author: Lally, Níall
ORCID: Lally, Níall
Nugent, Allison C
Niciu, Mark J
Roiser, Jonathan P
Zarate, Carlos A
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2015-02-17
Volume: 29
Issue: 5
Pages: 596-607
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881114568041
PMC: PMC5116382
OpenAlex: W2113067674
Cited by: 224
References: 70
Citations by year: 2026: 6 · 2025: 13 · 2024: 32 · 2023: 20 · 2022: 33 · 2021: 27 · 2020: 18 · 2019: 22 · 2018: 15 · 2017: 12 · 2016: 19 · 2015: 7
FWCI: 12.63
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: National Institutes of Health
U.S. Public Health Service (04-M-0222)
National Institute of Mental Health (ZIAMH002857)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: ketamine, anhedonia, major depressive disorder, treatment-resistant depression, rapid-acting antidepressants, riluzole, glucose metabolism, hippocampus, dorsal anterior cingulate cortex, orbitofrontal cortex, inferior frontal gyrus, neural correlates, FDG-PET
MeSH terms: Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Gyrus Cinguli, Hippocampus, Humans, Ketamine, Male, Middle Aged, Radionuclide Imaging, Treatment Outcome, Anhedonia, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks